Legence price target raised to $90 from $62 at BofA

BofA raised the firm’s price target on Legence (LGN) to $90 from $62 and keeps a Buy rating on the shares. While shares are up 87% year-to-date, the firm sees further upside potential ahead as Legence “sits at the intersection” of the key secular themes of the data center buildout and pharma reshoring, the analyst tells investors.